101 related articles for article (PubMed ID: 17726033)
1. COX-2 inhibitor.
Gøtzsche PC; Bjarnason NH
Rheumatology (Oxford); 2007 Oct; 46(10):1623-4; author reply 1624-5. PubMed ID: 17726033
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
[TBL] [Abstract][Full Text] [Related]
3. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
Bingham CO; Smugar SS; Wang H; Tershakovec AM
Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
[TBL] [Abstract][Full Text] [Related]
4. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Wall R; Strickland C; Jamieson B; Lo V
J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
[No Abstract] [Full Text] [Related]
5. Use and misuse of the p-value.
Lesaffre E
Bull NYU Hosp Jt Dis; 2008; 66(2):146-9. PubMed ID: 18537787
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Krüger K
MMW Fortschr Med; 2005 Aug; 147(31-32):28-30. PubMed ID: 16128193
[TBL] [Abstract][Full Text] [Related]
7. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
Gómez de la Fuente E; Pampín Franco A; Caro Gutiérrez D; López Estebaranz JL
Actas Dermosifiliogr; 2014 Apr; 105(3):314-5. PubMed ID: 24661957
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
Sakamoto C; Soen S
Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
[TBL] [Abstract][Full Text] [Related]
10. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
Hinz B; Dormann H; Brune K
Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
[TBL] [Abstract][Full Text] [Related]
11. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Wooltorton E
CMAJ; 2002 Jun; 166(13):1692-3. PubMed ID: 12126328
[No Abstract] [Full Text] [Related]
12. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
13. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
14. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
15. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
16. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Krüger K
MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
[No Abstract] [Full Text] [Related]
17. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
[No Abstract] [Full Text] [Related]
18. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.
Zweers MC; de Boer TN; van Roon J; Bijlsma JW; Lafeber FP; Mastbergen SC
Arthritis Res Ther; 2011; 13(5):239. PubMed ID: 21955617
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibitor, celecoxib, may prevent lung cancer.
Oncology (Williston Park); 2011 Aug; 25(9):848-9. PubMed ID: 21936449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
